Turing Micro-Invasive Completes RMB 10 Million Angel Funding Round to Accelerate Smart Surgical Device Portfolio

VCBeat has learned that Turing Minimally Invasive, an innovative enterprise specializing in intelligent surgical devices, recently announced the completion of its angel financing round, raising RMB 10 million. The round was solely invested by Lingxian Health Fund. The funds will primarily be used to expand the R&D team and accelerate the development of multiple innovative surgical products.

Beijing Turing Minimally Invasive Medical Technology Co., Ltd., established in 2019 and located at the Zhongguancun Institute of Emerging Industry Frontier Technologies—a high-end manufacturing base in Beijing—is a technology-driven enterprise engaged in the research and development, production, and operation of intelligent innovative surgical equipment. Committed to innovating surgical devices with a focus on enhancing surgical safety and improving operating room efficiency, the company has launched a product line designed to upgrade the laparoscopic surgical experience, which has been installed in over 100 hospitals across 24 provinces in China. Meanwhile, its pipeline of products under development, including innovative solutions for thyroid and breast surgery, is progressing steadily.

The company’s founding team comprises senior marketing executives from globally renowned minimally invasive surgery companies, robotics scientists, and specialized engineers with aerospace backgrounds. The company possesses comprehensive capability models across research and development, production, and commercialization—a rarity among startups. Within two years of its establishment, the company successfully launched and generated sales from its first independently developed product, achieving financial self-sufficiency and demonstrating strong momentum in performance growth.

The Chief Scientist of Turing Minimally Invasive is an expert in robotics and machine vision who studied in France for many years. He has long been engaged in machine vision research at top European institutes and has published more than 20 papers in internationally prominent journals and conferences. The product development team of Turing Minimally Invasive consists of senior engineers graduated from prestigious universities such as Beihang University, Zhejiang University, and Harbin Institute of Technology, with over 80% of the R&D staff holding master’s degrees or higher. Many team members come from global leading medical device companies including GE, Johnson & Johnson, Stryker, and Olympus.

Meanwhile, Turing Minimally Invasive has achieved significant breakthroughs in industry-academia collaboration. In 2021, it entered into a strategic partnership with the Advanced Innovation Center for Biomedical Engineering at Beihang University, becoming a key pilot enterprise for the translation and implementation of medical-engineering interdisciplinary technologies under the Zhongguancun Institute of Frontier Technologies for Emerging Industries. Currently, the joint project with Beihang University’s Institute of Medical Photonics to commercialize parathyroid detection equipment has been officially launched.

Mr. Lin Youjia, Founder and CEO of Turing Minimally Invasive, stated: “We position Turing Minimally Invasive as a technology-driven company dedicated to innovative minimally invasive surgical devices. ‘Innovation’ is our core value orientation. We identify unmet needs in China’s minimally invasive surgery market, strive to develop products tailored to the Chinese market environment, and achieve market breakthroughs through efficient clinical education. Each of these three steps requires innovation; simply copying and pasting imported products is not what Turing Minimally Invasive aims to do.”

Mr. Chen Xi, R&D Director at Turing Minimally Invasive, stated, “The R&D team at Turing Minimally Invasive comprises professionals with backgrounds in Fortune 500 medical device and aerospace industries. The team has consistently adhered to high-standard development processes and methodologies for medical devices, taking into comprehensive consideration product functional parameters, safety design, regulatory compliance, manufacturability, and maintainability. This ensures that each of Turing Minimally Invasive’s innovative medical products not only meets clinical needs but also delivers reliability and user experience on par with imported products.”

Mr. Wu Jialu, Founding Partner of Lingxian Health Fund, stated, “Minimally invasive surgery has established a solid foundation of clinical awareness and application in China to date. With the rapid adoption of minimally invasive surgical procedures, the industry is transitioning from an era of extensive growth to one characterized by refinement and specialization. Clinical practice has generated new demands for enhancing surgical experience and developing specialized instruments. Turing Minimally Invasive has keenly recognized the signals of this new industry wave and become one of the earliest companies in China to engage in this field. The company’s founders each possess over ten years of experience in the minimally invasive surgery sector and demonstrate strong innovative spirit. We look forward to Turing Minimally Invasive’s outstanding performance.”

Lingxian Health is a venture capital fund founded by seasoned medical investment professionals, dedicated to early-stage investments in the healthcare and medical industry. Adhering to the philosophy of “focus and professionalism,” we deeply explore development trends and investment opportunities within the healthcare sector, filtering out noise and distractions to pursue genuine investment returns.